A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Abstract Background Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat with azacitidine and venetoclax. Methods This si...

Full description

Bibliographic Details
Main Authors: Nicholas J. Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D. Dinardo, Gautam Borthakur, Nitin Jain, Maro Ohanian, Elias Jabbour, Ghayas C. Issa, Wei Qiao, Xuelin Huang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Prithviraj Bose, Farhad Ravandi, Ricardo Delumpa, Regina Abramova, Guillermo Garcia-Manero, Michael Andreeff, Jorge Cortes, Hagop Kantarjian
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Journal of Hematology & Oncology
Subjects:
Protein neddylation
Elderly
Myeloid diseases
Therapy
Clinical trial
Online Access:https://doi.org/10.1186/s13045-023-01476-8

Internet

https://doi.org/10.1186/s13045-023-01476-8

Similar Items